Frequency and cost of adverse events in renal cell carcinoma (RCC) patients receiving angiogenesis inhibitor therapies
Dial E, Fournier A, Moyneur E, Neary M, Duh M, Oh W. Frequency and cost of adverse events in renal cell carcinoma (RCC) patients receiving angiogenesis inhibitor therapies. Journal Of Clinical Oncology 2008, 26: 14609-14609. DOI: 10.1200/jco.2008.26.15_suppl.14609.Peer-Reviewed Original ResearchRenal cell carcinomaAngiogenesis inhibitor therapyCosts of adverse eventsInhibitor therapyCell carcinoma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply